The impact of cognitive-behavioral treatment on the mental health and quality of life of cancer patients.

Positive Phase 2a Fibromyalgia Results Deliver Pain Reduction in 100% of Patients, Strengthening IP Position and Clinical Trial Strategy Tryptamine...

CAMBRIDGE, Mass., Aug. 13, 2024. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on transforming cardiometabolic...

India's first phase-three trial for an indigenous tetravalent dengue vaccine, DengiALL, was initiated by Panacea Biotec. Conducted across 19 sites,...

Pharmadrug Inc (CSE: PHRX) has received approval for its majority owned joint venture, Sairiyo Therapeutics, to process with a Phase 1 clinical study...

TUESDAY, Aug. 12, 2024 -- An experimental drug based on ancient Chinese herbal medicine can help ease the toxic side effects of chemotherapy and...

Vorasidenib has been approved by the U.S. Food and Drug Administration (FDA) for patients with Grade 2 gliomas with IDH1 or IDH2 mutations. Based...

The FDA approves a new glioma therapy for the first time in decades, offering renewed hope for patients with this challenging brain cancer.

Olive Doyle was admitted to St Vincent’s last October suffering from malignant melanoma before complications contributed to her death

Chimeric antigen receptor (CAR) T–cell immunotherapy re-engineers a patient’s immune cells to target cancer cells. While successful in some types...